ArticleArthroplasty today2026
Allergic Contact Dermatitis to 2-Octyl Cyanoacrylate After Total Joint Arthroplasty: A Single-Surgeon Case Series.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 2-Octyl cyanoacrylate is widely used for surgical skin closure in orthopaedic procedures, offering advantages such as ease of application, strong adherence, and favorable cosmetic outcomes. However, allergic contact dermatitis (ACD) is a rare yet recognized complication resulting in topical and systemic treatments and a theoretical risk for superficial and deep periprosthetic joint infection (PJI). Methods: This retrospective case series analyzes patients who developed hypersensitivity reactions to 2-octyl cyanoacrylate following primary hip and knee arthroplasty performed by a single surgeon between 2017 and 2024. Only cases with photo documentation and a minimum of 6 weeks follow-up were included. Results: We identified 2,789 (total hip arthroplasty = 1270, total knee arthroplasty = 1516) hip and knee arthroplasty procedures utilizing 2-octyl cyanoacrylate. Among these, 15 patients (0.54%) developed ACD (6 after hip and 9 after knee arthroplasties). The mean onset time was 11.7 days; average resolution occurred at 27.4 days. All cases were managed conservatively with topical and oral therapies. No PJIs or reoperations occurred. Wounds achieved excellent cosmesis with only one patient with persistent skin discoloration. Conclusions: ACD due to 2-octyl cyanoacrylate skin glue is uncommon and generally self-limiting when appropriately diagnosed and managed and does not go on to superficial or deep PJI. Surgeons should be aware of this complication and educate patients to facilitate early identification and treatment. Hypoallergenic alternatives may be considered in future elective orthopaedic surgery; however, comparative products must also achieve the exceptional safety profile of 2-octyl cyanoacrylate in regard to superficial or deep PJI. Level of Evidence: Level IV, Case Series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.